Dr. Dwyer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Division of Nephrology & Hypertension
30 N 1900 E, Room 4R312
Salt Lake City, UT 84132Phone+1 801-581-7606- Is this information wrong?
Summary
- I am currently Professor of Medicine at the University of Utah in the Clinical and Translational Sciences Institute. My research focuses on the design, conduct, and analysis of large-scale randomized clinical trials in nephrology and hypertension, particularly in delaying the progression of CKD. I am the current President/PI of the Collaborative Study Group (CSG), a international academic research organization (ARO) dedicated to the exceptionally rigorous design and analysis and safe conduct of pilot and multinational, large-scale, pivotal RCTs in relevant therapeutic areas, including CKD, diabetic nephropathy, lupus, lupus nephritis, and end-stage renal disease. My expertise centers around protocol design and endpoint selection/design, medical monitoring, trial conduct, and safety. I have analyzed renal safety signals in non-renal clinical trials presented to FDA, as well as sat on FDA Advisory Committees. I am interested in investigating alternative, proximal outcomes in large RCTs in nephrology which will increase event rates, reduce follow-up time, and reduce sample sizes, in order to speed intervention development to delay the progression of CKD. Finally, as part of this interest in endpoint analysis, I am interested in the measurement of renal function and its implications for the design and choice of endpoints in large RCTs, particularly as it relates to assessment of nephrotoxicity ascertainment. I am a practicing nephrologist who cares for CKD and dialysis patients across the care continuum. In 2017, we founded Innovative Renal Care. Until 2022, I was Director of the Nephrology Clinical Trials Center at Vanderbilt University Medical Center.
Education & Training
- Vanderbilt University Medical CenterFellowship, Nephrology, 2004 - 2006
- Mayo Clinic College of Medicine and Science (Jacksonville)Chief Residency, Internal Medicine, 2003 - 2004
- Mayo Clinic College of Medicine and Science (Jacksonville)Residency, Internal Medicine, 2000 - 2003
- The Warren Alpert Medical School of Brown UniversityClass of 2000
- Brown UniversityScB, Mathematics and Classics:Latin, 1992 - 1996
Certifications & Licensure
- UT State Medical License 2021 - 2026
- TN State Medical License 2008 - 2023
- AL State Medical License 2020 - 2020
- FL State Medical License 2001 - 2009
- KY State Medical License 2005 - 2007
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Nephrology
Clinical Trials
- Effect of Sulodexide in Early Diabetic Nephropathy Start of enrollment: 2005 Aug 01
- Effect of Sulodexide in Overt Diabetic Nephropathy Start of enrollment: 2005 Aug 01
- A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) Start of enrollment: 2008 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsEffect of Intensive Blood Pressure Control on Kidney Outcomes: Long-Term Electronic Health Record-Based Post-Trial Follow-Up of SPRINT.Paul E Drawz, Kristin M Lenoir, Nayanjot Kaur Rai, Anjay Rastogi, Chi D Chu, Frederic F Rahbari-Oskoui, Paul K Whelton, George Thomas, Andrew McWilliams, Anil K Agarwa...> ;Clinical Journal of the American Society of Nephrology. 2023 Oct 25
- 6 citationsEfficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.Hiddo J L Heerspink, Peter J Greasley, Christine Ahlström, Magnus Althage, Jamie P Dwyer, Gordon Law, Emma Wijkmark, Min Lin, Anne-Kristina Mercier, Mikael Sunnåker, M...> ;Nephrology, Dialysis, Transplantation. 2024 Feb 28
- 4 citationsRisk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes.Filipe A Moura, David D Berg, Andrea Bellavia, Jamie P Dwyer, Ofri Mosenzon, Benjamin M Scirica, Stephen D Wiviott, Deepak L Bhatt, Itamar Raz, Mark W Feinberg, Eugene...> ;Diabetes Care. 2023 Oct 1
- Join now to see all
Hospital Affiliations
- University of Utah HealthSalt Lake City, Utah
- University of Utah HealthSalt Lake City, Utah
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: